MSD conducted 140 clinical research projects in China in 2022, bolstering the country’s progress in the sector. — China Daily
Beijing: With a long-term commitment to the Chinese market, US-based global pharmaceutical company Merck Sharp & Dohme (MSD) plans to introduce over 50 innovative drugs, vaccines, and companion diagnostics to China in the next five years.
As part of its constant efforts to enhance its local research and development (R&D) capabilities, MSD conducted 140 clinical research projects in China in 2022, bolstering the country’s progress in the sector .
